Which of the following immunotherapy approaches has demonstrated great potential in early clinical trials in patients with B-cell leukemia?
Chimeric antigen receptors (CAR)
Lymphokine-activated killer (LAK) cells
T-cell receptors (TCR)
Tumor-infiltrating lymphocytes (TILs)
